Receptor News and Research

RSS

Scientists use two different methods to visualize rare CTCs, double positive cells in mBC

New research from The Ohio State University utilizes two different methods to visualize circulating tumor cells (CTCs) as well as other unusual circulating cells with both epithelial and hematopoietic characteristics in metastatic breast cancer.

12 Apr 2012

Losartan may not increase risk of all-cause mortality in heart failure patients

Although observational studies have suggested that losartan, a drug used primarily for the treatment of hypertension, may be associated with an increased risk of death among patients with heart failure compared with other medications in the same class of drugs (angiotensin II receptor blockers [ARBs]), an analysis that included nearly 6,500 patients found that overall, use of losartan was not associated with increased all-cause death or cardiovascular death compared with use of the ARB candesartan, according to a study in the April 11 issue of JAMA.

11 Apr 2012

NIH awards Winston SBIR grant to develop Civamide for postherpetic neuralgia of TN

Winston Pharmaceuticals, Inc.,, announced that the National Institutes of Health has awarded Winston a grant under the Small Business Innovation Research program supporting the development of Civamide, a proprietary TRPV-1 receptor modulator, for the treatment of postherpetic neuralgia of the trigeminal nerve.

9 Apr 2012

Researchers question wisdom of blocking DP1 in patients prone to cardiovascular disease

Niacin, or vitamin B3, is the one approved drug that elevates "good" cholesterol (high density lipoprotein, HDL) while depressing "bad" cholesterol (low density lipoprotein , LDL), and has thereby attracted much attention from patients and physicians. Niacin keeps fat from breaking down, and so obstructs the availability of LDL building blocks.

9 Apr 2012

Researchers discover two molecules that control liver glucose production

In their extraordinary quest to decode human metabolism, researchers at the Salk Institute for Biological Studies have discovered a pair of molecules that regulates the liver's production of glucose---- the simple sugar that is the source of energy in human cells and the central player in diabetes.

9 Apr 2012

Zalicus' cHTS platform identifies synergistic drug combinations for treatment of cancer

Adenosine A2A and beta-2 adrenergic receptor agonists are highly synergistic and selective novel agents that enhance glucocorticoid activity in B-cell malignancies such as multiple myeloma and, importantly, can synergize in combination with current multiple myeloma treatment regimens such as melphalan, lenalidomide, bortezomib and doxorubicin.

6 Apr 2012

African American women more likely to have ER-negative breast cancer

American women of African ancestry are more likely than European Americans to have estrogen-receptor-negative (ER-negative) breast cancer. There continues to be discussion about the role of low levels of vitamin D in the development of breast cancer for these women.

6 Apr 2012

New microfluidics-based microarray can accurately detect breast cancer

One in eight women will be diagnosed with breast cancer during her lifetime. The earlier cancer is detected, the better the chance of successful treatment and long-term survival. However, early cancer diagnosis is still challenging as testing by mammography remains cumbersome, costly, and in many cases, cancer can only be detected at an advanced stage.

6 Apr 2012

USPTO issues patent to ChromaDex’s pterostilbene

The U.S. Patent and Trademark Office has granted patent #8,133,917 pertaining to the ingredient pterostilbene, which is licensed exclusively to ChromaDex Corp., an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, and marketer of BluScience, its new line of dietary supplements.

6 Apr 2012

Opportunity for developers and marketers of EGFR inhibitors in Brazil and Mexico

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that patient access to premium-priced targeted cancer treatments in Brazil and Mexico is improving, creating an opportunity for developers and marketers of epidermal growth factor receptor (EGFR) inhibitors.

5 Apr 2012

ARI-4175 drug may treat colorectal cancer patients with KRAS mutation

When combined with other treatments, the drug cetuximab-which works by slowing or stopping the growth of cancer cells-has been shown to extend survival in certain types of cancer, including metastatic colorectal cancers. Unfortunately, about 40 percent of colorectal cancer patients-specifically those who carry a mutated form of a gene called KRAS-do not respond to the drug. Researchers at Fox Chase Cancer Center in Philadelphia, however, have been working on a way to overcome this resistance to cetuximab by unleashing a second cetuximab driven mechanism using a novel drug called ARI-4175.

5 Apr 2012

VCAM1 nanobodies can effectively visualize atherosclerotic lesions

In collaboration with a Brussels University team under the leadership of Nick Devoogdt and a French team from INSERM, Serge Muyldermans and his team, associated with VIB and Vrije Universiteit Brussel, have succeeded in developing the first patient-friendly, non-invasive method for differentiating dangerous strictures in blood vessels, so-called vulnerable atherosclerotic plaques, from less dangerous ones.

5 Apr 2012

Olanzapine improves survival in mouse model of anorexia nervosa

Low doses of a commonly used atypical antipsychotic drug improved survival in a mouse model of anorexia nervosa, University of Chicago researchers report this month. The result offers promise for a common and occasionally fatal eating disorder that currently lacks approved drugs for treatment.

5 Apr 2012

Drugs that target cholesterol pathway may enhance cancer-killing potential of chemotherapy drugs

Johns Hopkins investigators are testing a way to use drugs that target a cholesterol pathway to enhance the cancer-killing potential of standard chemotherapy drugs. Their tests, in mouse models of pancreatic cancer, may yield new and more effective combinations of current and possibly new anti-cancer drugs.

4 Apr 2012

Researchers identify how neural cells build up resistance to opioid pain drugs within hours

Researchers at the University of Montreal's Sainte-Justine Hospital have identified how neural cells are able to build up resistance to opioid pain drugs within hours. "A better understanding of these mechanisms will enable us to design drugs that avoid body resistance to these drugs and produce longer therapeutic responses, including prolonged opioid analgesia", lead author Dr. Graciela Pineyro said.

4 Apr 2012

Positive preclinical results from Cancer Therapeutics' CTX-0294945 plus Avastin study

Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced positive preclinical results for CTX-0294945 as an adjuvant therapy to the cancer drug Avastin (bevacizumab - Genentech/Roche). The data is presented today in a late breaking poster at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, USA.

4 Apr 2012

Removing SR-BI receptor may help protect against breast cancer

Removing a lipoprotein receptor known as SR-BI may help protect against breast cancer, as suggested by new findings presented at the American Association for Cancer Research Annual Meeting 2012 by Jefferson's Kimmel Cancer Center researchers.

4 Apr 2012

BioScale presents data on phospho-protein analysis of MAP kinase pathway activation state at 103rd AACR

BioScale, Inc. a life science company that develops ultrasensitive protein analysis technology, presented findings of recently completed research studies on phospho-protein analysis of the activation state of the MAP kinase pathway at the 103rd Annual Meeting of the American Association for Cancer Research (AACR), held at McCormick Place in Chicago, Illinois, March 31 - April 4, 2012.

3 Apr 2012

Lilly announces results of three preclinical studies that focus on c-MET receptor

Eli Lilly and Company today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell.

3 Apr 2012

Study shows how morphine creates inflammatory response in the brain

An international team of researchers involving the University of Adelaide and University of Colorado has made a major discovery that could lead to more effective treatment of severe pain using morphine.

3 Apr 2012

Receptor News and Research

Scientists use two different methods to visualize rare CTCs, double positive cells in mBC

Losartan may not increase risk of all-cause mortality in heart failure patients

NIH awards Winston SBIR grant to develop Civamide for postherpetic neuralgia of TN

Researchers question wisdom of blocking DP1 in patients prone to cardiovascular disease

Researchers discover two molecules that control liver glucose production

Zalicus' cHTS platform identifies synergistic drug combinations for treatment of cancer

African American women more likely to have ER-negative breast cancer

New microfluidics-based microarray can accurately detect breast cancer

USPTO issues patent to ChromaDex’s pterostilbene

Opportunity for developers and marketers of EGFR inhibitors in Brazil and Mexico

ARI-4175 drug may treat colorectal cancer patients with KRAS mutation

VCAM1 nanobodies can effectively visualize atherosclerotic lesions

Olanzapine improves survival in mouse model of anorexia nervosa

Drugs that target cholesterol pathway may enhance cancer-killing potential of chemotherapy drugs

Researchers identify how neural cells build up resistance to opioid pain drugs within hours

Positive preclinical results from Cancer Therapeutics' CTX-0294945 plus Avastin study

Removing SR-BI receptor may help protect against breast cancer

BioScale presents data on phospho-protein analysis of MAP kinase pathway activation state at 103rd AACR

Lilly announces results of three preclinical studies that focus on c-MET receptor

Study shows how morphine creates inflammatory response in the brain

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News